Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.

Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG.

Cancer Immunol Res. 2017 Jul;5(7):535-546. doi: 10.1158/2326-6066.CIR-16-0309. Epub 2017 May 23.

2.

Checkpoint Blockade in Lung Cancer and Mesothelioma.

Lievense LA, Sterman DH, Cornelissen R, Aerts JG.

Am J Respir Crit Care Med. 2017 Aug 1;196(3):274-282. doi: 10.1164/rccm.201608-1755CI. Review.

PMID:
28252315
3.

Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Dammeijer F, Lievense LA, Veerman GD, Hoogsteden HC, Hegmans JP, Arends LR, Aerts JG.

J Clin Oncol. 2016 Sep 10;34(26):3204-12. doi: 10.1200/JCO.2015.66.3955. Epub 2016 Jul 18. Review.

PMID:
27432922
4.

Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression.

Lievense LA, Cornelissen R, Bezemer K, Kaijen-Lambers ME, Hegmans JP, Aerts JG.

J Thorac Oncol. 2016 Oct;11(10):1755-64. doi: 10.1016/j.jtho.2016.06.021. Epub 2016 Jul 12.

5.

Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.

Lievense LA, Bezemer K, Cornelissen R, Kaijen-Lambers ME, Hegmans JP, Aerts JG.

Lung Cancer. 2017 May;107:36-40. doi: 10.1016/j.lungcan.2016.04.015. Epub 2016 Apr 27.

PMID:
27168021
6.

Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.

Cornelissen R, Lievense LA, Robertus JL, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG.

Lung Cancer. 2015 Jun;88(3):332-7. doi: 10.1016/j.lungcan.2015.03.013. Epub 2015 Mar 21.

PMID:
25843042
7.

Immunotherapy prospects in the treatment of lung cancer and mesothelioma.

Aerts JG, Lievense LA, Hoogsteden HC, Hegmans JP.

Transl Lung Cancer Res. 2014 Feb;3(1):34-45. doi: 10.3978/j.issn.2218-6751.2013.11.04. Review.

8.

Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.

Cornelissen R, Lievense LA, Maat AP, Hendriks RW, Hoogsteden HC, Bogers AJ, Hegmans JP, Aerts JG.

PLoS One. 2014 Sep 5;9(9):e106742. doi: 10.1371/journal.pone.0106742. eCollection 2014.

9.

Biomarkers for immune checkpoint inhibitors.

Lievense LA, Hegmans JP, Aerts JG.

Lancet Oncol. 2014 Jan;15(1):e1. doi: 10.1016/S1470-2045(13)70557-6. No abstract available.

PMID:
24384488
10.

Tumor-associated macrophages in thoracic malignancies.

Lievense LA, Bezemer K, Aerts JG, Hegmans JP.

Lung Cancer. 2013 Jun;80(3):256-62. doi: 10.1016/j.lungcan.2013.02.017. Epub 2013 Mar 13. Review.

PMID:
23489559
11.

Dendritic cell-based immunotherapy in mesothelioma.

Cornelissen R, Lievense LA, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG.

Immunotherapy. 2012 Oct;4(10):1011-22. doi: 10.2217/imt.12.108. Review.

PMID:
23148753

Supplemental Content

Loading ...
Support Center